Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (142)	10/31/1997 2:35:00 AM
From: John Dwyer	Read Replies (1) \| Respond to of 496

Did anyone check out the article by Mark Edwards of Recombinant Capital regarding the Amgen/GLFD deal? recap.com It's a pretty realistic view about what the deal really means for GLFD and makes the point that while the deal is very good for GLFD, it is not as spectacular as the press made it out to be. That said, I do think that GLFD below $25 is a good long-term buy. I haven't bought any myself, I've been concentrating on Depotech and ArQule, but may be tempted if it drops into the low 20's again. John